The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Top MPN highlights from ASH 2024 & trials to look out for in 2025: expert insights
In this exclusive video compilation, hear directly from leading experts as they share their top highlights in myeloproliferative neoplasms (MPNs) from the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. This roundup features:
• Claire Harrison, who highlights the importance of increasing our understanding of MPN genomics, the excitement around novel JAK inhibitors, and promising ongoing trials, including the MANIFEST trial (NCT02158858);
• John Mascarenhas, who highlights the impact of TP53 mutations in patients with MPNs, novel JAK inhibitor and non-JAK inhibitor therapies, and immunotherapeutic approaches;
• Prithviraj Bose, who discusses research on CALR variant allele frequency (VAF) dynamics, findings from the FREEDOM2 study (NCT03952039), and rethinking risk stratification in polycythemia vera (PV);
• Lucia Masarova, who discusses the excitement regarding the combination of ruxolitinib and selinexor, the BOREAS trial (NCT03662126), and other novel agents, including nuvisertib.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
